1. Home
  2. AVDL vs DCBO Comparison

AVDL vs DCBO Comparison

Compare AVDL & DCBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • DCBO
  • Stock Information
  • Founded
  • AVDL 2015
  • DCBO 2016
  • Country
  • AVDL Ireland
  • DCBO Canada
  • Employees
  • AVDL N/A
  • DCBO N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • DCBO
  • Sector
  • AVDL Health Care
  • DCBO
  • Exchange
  • AVDL Nasdaq
  • DCBO Nasdaq
  • Market Cap
  • AVDL 900.2M
  • DCBO 793.9M
  • IPO Year
  • AVDL 1996
  • DCBO 2020
  • Fundamental
  • Price
  • AVDL $9.54
  • DCBO $28.51
  • Analyst Decision
  • AVDL Strong Buy
  • DCBO Strong Buy
  • Analyst Count
  • AVDL 6
  • DCBO 5
  • Target Price
  • AVDL $18.17
  • DCBO $42.20
  • AVG Volume (30 Days)
  • AVDL 1.6M
  • DCBO 75.0K
  • Earning Date
  • AVDL 08-07-2025
  • DCBO 08-07-2025
  • Dividend Yield
  • AVDL N/A
  • DCBO N/A
  • EPS Growth
  • AVDL N/A
  • DCBO 268.72
  • EPS
  • AVDL N/A
  • DCBO 0.74
  • Revenue
  • AVDL $194,450,000.00
  • DCBO $222,824,000.00
  • Revenue This Year
  • AVDL $56.88
  • DCBO $13.57
  • Revenue Next Year
  • AVDL $29.81
  • DCBO $13.40
  • P/E Ratio
  • AVDL N/A
  • DCBO $38.46
  • Revenue Growth
  • AVDL 252.64
  • DCBO 16.79
  • 52 Week Low
  • AVDL $6.38
  • DCBO $25.50
  • 52 Week High
  • AVDL $17.30
  • DCBO $53.86
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 56.42
  • DCBO 52.83
  • Support Level
  • AVDL $8.74
  • DCBO $27.80
  • Resistance Level
  • AVDL $9.56
  • DCBO $29.61
  • Average True Range (ATR)
  • AVDL 0.39
  • DCBO 0.72
  • MACD
  • AVDL 0.04
  • DCBO 0.14
  • Stochastic Oscillator
  • AVDL 81.92
  • DCBO 68.84

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

Share on Social Networks: